Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SYN Stock Forecast 2026-2027
$0.23
Current Price
$0
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to SYN Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
SYN Price Momentum
-4.2%
1 Week Change
-20.7%
1 Month Change
-51.1%
1 Year Change
+9.5%
Year-to-Date Change
-72.9%
From 52W High of $0.86
+43.7%
From 52W Low of $0.16
📊 TOP ANALYST CALLS
Did SYN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Synthetic Biologics is one of their latest high-conviction picks.
Latest SYN Stock Price Targets & Analyst Predictions
SYN has shown a year-to-date change of 9.5% and a 1-year change of -51.1%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for SYN. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SYN Analyst Ratings
3
Buy
0
Hold
0
Sell
SYN Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $0.23
Latest SYN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SYN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 12, 2021 | Maxim Group | Jason McCarthy | Buy | Upgrade | $N/A |
| Oct 5, 2020 | Maxim Group | Jason McCarthy | Hold | Downgrade | $N/A |
| May 10, 2018 | Griffin Securities | Hold | Downgrade | $N/A |
Synthetic Biologics Inc (SYN) Competitors
The following stocks are similar to Synthetic Biologics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
SYN
Synthetic Biologics
mkt cap
5.00M
Synthetic Biologics Inc (SYN) Financial Data
Valuation Metrics
Market Cap
$0
Enterprise Value
$-65,798,000
P/E Ratio
-0.1x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
EPS Growth
N/A
Financial Health
Cash/Price Ratio
N/A
Current Ratio
5.0x
Debt/Equity
0.0x
ROE
+8.6%
ROA
-33.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Synthetic Biologics Inc (SYN) Business Model
About Synthetic Biologics Inc
What They Do
N/A
Business Model
N/A
Additional Information
N/A
Company Information
Sector
Industry
Employees
0
CEO
Country
United States
IPO Year
2006
Website
www.syntheticbiologics.comSynthetic Biologics Inc (SYN) Latest News & Analysis
Latest News
Quick Summary
The rebrand enhances a focused clinical development strategy for oncolytic viruses designed for intravenous administration.
Why It Matters
The rebranding signals a focused approach on innovative cancer treatments, potentially enhancing market positioning and attracting investment interest in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Preclinical results show that topotecan enhances the oncolytic activity of VCN-01 against retinoblastoma, indicating potential for improved cancer treatment.
Why It Matters
Positive preclinical results for VCN-01 combined with topotecan could signal advancements in cancer treatment, potentially leading to increased stock value and interest in biotech investments.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The DSMC has approved the continuation of the study, allowing patient enrollment into Cohort 2 after reviewing safety and pharmacokinetic data from Cohort 1.
Why It Matters
Progress in clinical trials can signal potential advancements in drug development, impacting stock prices and market confidence in the company's future profitability.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
VCN-01 combined with durvalumab shows an acceptable safety profile and promising biological activity, indicating potential for further development in treatments.
Why It Matters
Positive results for VCN-01 with durvalumab suggest potential for new cancer therapies, indicating growth opportunities for biotech firms and possible stock price increases in related companies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q2 2022 Results - Earnings Call Transcript
3 years ago
Quick Summary
Synthetic Biologics, Inc. (NYSE:SYN) held its Q2 2022 earnings call on August 11, 2022, featuring key executives and analysts discussing company performance and outlook.
Why It Matters
The earnings call provides insights into Synthetic Biologics' financial performance and strategic direction, which can influence stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Synthetic Biologics Reports Second Quarter 2022 Operational Highlights and Financial Results
3 years ago
Quick Summary
A company is focusing on the development of a novel oncolytic adenovirus platform, which could have implications for cancer treatment advancements.
Why It Matters
Advancements in oncolytic adenovirus platforms may lead to breakthroughs in cancer treatment, potentially increasing the market value of biotech companies involved and attracting investment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About SYN Stock
What is Synthetic Biologics Inc's (SYN) stock forecast for 2027?
Analyst forecasts for Synthetic Biologics Inc (SYN) are not currently available. The stock is trading at $0.23.
Is SYN stock a good investment in 2027?
According to current analyst ratings, SYN has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.23. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SYN stock?
Price predictions from Wall Street analysts for SYN are not currently available. The stock is trading at $0.23.
What is Synthetic Biologics Inc's business model?
N/A
What is the highest forecasted price for SYN Synthetic Biologics Inc?
Price targets from Wall Street analysts for SYN are not currently available. The stock is trading at $0.23.
What is the lowest forecasted price for SYN Synthetic Biologics Inc?
Price targets from Wall Street analysts for SYN are not currently available. The stock is trading at $0.23.
What is the overall SYN consensus from analysts for Synthetic Biologics Inc?
The overall analyst consensus for SYN is bullish. Out of 2 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell.
How accurate are SYN stock price projections?
Stock price projections, including those for Synthetic Biologics Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 14, 2026 4:20 PM UTC